Loading patent…
OwnerLuis Rodriguez-Borlado, Houman Hemmati +3inventors
InventorsLuis Rodriguez-Borlado, Houman Hemmati, Kiel A. Peck, Linda Marban, Jennifer J. Moseley
Estimating the term…
The present invention relates to a method of treating acute or chronic systemic graft-versus-host disease (GVHD) with extracellular vesicles, e.g., exosomes obtained from human cardiospheres or cardiosphere-derived cells (CDCs), wherein systemic GVHD involves, e.g., at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, genitalia, and eyes. The present invention also provides a pharmaceutical formulation comprising extracellular vesicles, e.g., exosomes obtained from human cardiospheres or CDCs, for systemic administration, e.g., intravenous infusion, to a human subject in need of treatment of systemic GVHD.
A method of treating systemic graft-versus-host disease (GVHD) in a subject in need thereof, the method comprising systemically administrating to the subject a therapeutically effective amount of extracellular vesicles, wherein said systemic GVHD is acute or chronic, wherein said extracellular vesicles express a natural killer cell (NK) activating receptor ligand, wherein said extracellular vesicles are obtained from cardiospheres, cardiosphere-derived cells (CDCs), or newt Al cell line, and wherein said NK activating receptor ligand is ULBP-2, 5, 6 or MIC-A/B.
A method of treating systemic GVHD in a subject in need thereof, the method comprising systemically administrating to the subject a therapeutically effective amount of extracellular vesicles derived from CDCs, wherein said extracellular vesicles derived from CDCs express a natural killer cell (NK) activating receptor ligand, and wherein said NK activating receptor ligand is ULBP-2, 5, 6 or MIC-A/B.
Dependencies are inferred from the claim text.